Doxapram for apnoea of prematurity and neurodevelopmental outcomes at age 5–6 years | ADC Fetal & Neonatal Edition

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens
Log in via RCPCH

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

Authors

Podcasts

About
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens
Log in via RCPCH

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Citation Tools

Original research

Doxapram for apnoea of prematurity and neurodevelopmental outcomes at age 5–6 years

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:: Tréluyer L, Zana-Taieb E, Jarreau P, et al

Doxapram for apnoea of prematurity and neurodevelopmental outcomes at age 5–6 years

Archives of Disease in Childhood - Fetal and Neonatal Edition 2024;109:443-449.